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Up to a third of patients undergoing coronary angiography for angina-like chest pain are found to have normal coronary arteries
and a substantial proportion of these individuals continue to consult and even attend emergency departments. Initially, these
patients are usually seen by cardiologists but with accumulating evidence that the pain might have a gastrointestinal origin, it may
be more appropriate for them to be cared for by the gastroenterologist once a cardiological cause has been excluded. This review
coverstheassessmentandmanagementofthischallengingcondition,whichincludesacombinationofeducation,reassurance,and
pharmacotherapy.Forthemorerefractorycases,behavioraltreatments,suchascognitivebehavioraltherapyorhypnotherapy,may
have to be considered.
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1. INTRODUCTION
Noncardiac chest pain (NCCP) is deﬁned as the presence
of pain resembling angina in the absence of evidence of
a n yc o r o n a r ya r t e r yd i s e a s e[ 1, 2]. The pain, which may
be relieved by glyceryl trinitrate (GTN), can radiate to the
arms or neck although it can be very diﬃcult to separate
NCCP from true cardiac pain [3]. However, a distinguishing
feature which can be useful is the radiation of the pain
to the back which is not so common in angina [4]. It is
important that cardiac disease is excluded at least by an
exercise stress test and, in many cases, it may be necessary
to undertake an angiogram. The latter is especially useful in
refractory cases so that physicians can be secure about their
reassurance as well as being conﬁdent in their therapeutic
approach. Nothing undermines management more than
endlessly repeating the cardiogram “just in case.”
2. ASSESSMENT
Because of its close relationship to the heart, the esophagus is
often incriminated in NCCP but this may not always be the
case.Gastroesophagealreﬂuxdisease(GERD)isprobablythe
commonestcauseofpainarisingfromtheesophagusandthis
can be assessed by pH monitoring although there has been a
recenttrendtoreplacethiswithatherapeutictrialofaproton
pump inhibitor (PPI) [5]. Gastroscopy is also worthwhile
[6] and perhaps we should be considering esophageal biopsy
more frequently in the light of the increasing number of
reports of eosinophilic esophagitis [7], as we know little
about the contribution of this problem to chest pain.
Routine blood tests are unlikely to be helpful although
barium studies of the esophagus may raise the suspicion
of a motility problem. It is possible to record the motility
of the esophagus or its sensitivity to either mechanical or
chemical (e.g., acidic) stimuli [8, 9] and although useful
for research purposes, this approach has not found a great
deal of utility in the routine investigation of NCCP. With
respect to motility recording, a number of diﬀerent contrac-
tion abnormalities of the esophagus have been described,
such as the nutcracker esophagus, although the temporal
relationship of these events to symptoms has not always been
clear cut. More recently, there has been increasing interest
in the phenomenon of nonacid esophageal reﬂux [10]b u t
its role in NCCP has not yet been deﬁned. This problem
can be identiﬁed by esophageal impedance monitoring [11]
although at present this technique tends to be conﬁned to
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Another important concept, especially from a thera-
peutic point of view, that is common to all functional
gastrointestinal disorders, is the notion that the central
processing of noxious stimuli from the gut is disturbed [12].
Thus, how the patient perceives and reacts to their pain
is critical and there is some evidence that this may be a
problem in patients with NCCP [13–16]. These patients
also exhibit a higher prevalence of psychopathology than
those with angina and a simple assessment by an instrument
such as the hospital anxiety depression scale (HAD) [17]
can be very useful. A dietary evaluation is also worthwhile
as certain foods or drinks may exacerbate the pain and
it has been shown that alcohol and nicotine can aﬀect
lower esophageal sphincter function [18, 19]. Furthermore,
it should be remembered that a range of medications might
exacerbate gastrointestinal symptoms in general as well as
esophageal symptoms in particular, so a drug history is
helpful.
3. MANAGEMENT
Once a cardiological cause for the pain has been ruled out,
an assessment along the lines already described should be
undertaken. Reassurance is crucial but these patients are
notoriously resistant to this because of the lethal connota-
tions of chest pain and the fear that something might have
been overlooked.
A trial of a PPI should be the ﬁrst pharmacological
step and these may be required at high doses such as
omeprazole 40mgtwice a day or equivalent. If the patient
responds, then GERD-related chest pain is the most likely
diagnosis and maintenance treatment may be required.
Failure to respond to a PPI suggests that acid reﬂux is
not the problem although obviously this does not exclude
nonacid reﬂux. In the absence of reﬂux, it is usually assumed
that the problem may be due to a disorder of motility or
sensation. On the assumption that esophageal contractions
may be contributing to the pain, a variety of treatments
aiming at relieving spasm have been evaluated. Drugs such
as GTN, long acting nitrates, and a variety of calcium
channel blockers have been tried with variable results and
some problems with side eﬀects [20, 21]. Nifedipine has
probablyreceivedthemostattention,probablybecauseofthe
demonstration of an eﬀect on esophageal motility [22, 23]
and this drug is sometimes worth a trial although there is no
convincing evidence of eﬃcacy.
There is a general consensus that antidepressants, partic-
ularly of the tricyclic variety, are valuable in irritable bowel
syndrome although the data supporting this view are rather
old [24, 25]. Not surprisingly, therefore, a variety of tricyclic
agents have been tried in NCCP although, as with the IBS
studies, these studies are somewhat dated. However, the
results have been consistently positive suggesting that these
drugshaveadeﬁniteroleinmanagingthecondition[26–28].
It is a usual practice in functional gastrointestinal disorders
touserelativelylowdosesoftricyclicantidepressantsstarting
with amitriptyline 10mg daily or equivalent. There is
evidence that selective serotonin reuptake inhibition can
reduce chemical and mechanical sensitivity of the esophagus
[29] although there has only been one study assessing the
eﬀect of this class of drug in NCCP, but this was encouraging
[30]. Benzodiazepines have also been shown to possibly
be beneﬁcial [31, 32]. This is probably because of their
anxiolytic properties as patients with NCCP have been
shown to be prone to panic disorder [33–36]. Unfortunately,
this group of drugs is out of favor at present because of
their addictive potential. However, if patients can be trusted
to take them on an “as necessary basis” when the pain is
especially severe, we ﬁnd that they have a role in NCCP
and other functional gastrointestinal disorders, as long as
they are used with caution. There has been recent interest
in the possibility that theophylline might have a role in the
treatment of NCCP [37], especially as it appears to increase
the threshold to balloon distension-induced pain in the
esophagus.Intheonetrialsofarreported,thedrugappeared
to signiﬁcantly relieve symptoms in a relatively small group
of patients [38]. There have also been some reports that
the injection of Botox might help spastic disorders of
the esophagus [39] although there have been no formal
controlled trials.
Behavioral treatments are being increasingly used in
functional gastrointestinal disorders and NCCP is no excep-
tion to this rule. There have been ﬁve studies of cognitive
behavioral therapy (CBT) in this condition all of which have
been positive [40–44]. Whether this form of treatment has
a long lasting eﬀect is not so certain although one of these
trials suggested beneﬁt may be sustained [38]. Another form
of treatment that is gaining some acceptability in FGD’s is
hypnotherapy [45, 46] and we have recently reported a trial
of this modality in a small group of highly selected patients
withNCCP[47].Theseresultswereveryencouragingandwe
have subsequently shown that the beneﬁcial eﬀects appear to
be long lasting [44, 48].
Thus, in summary, it is mandatory to exclude a cardiac
causeforchestpainbeforeundertakingappropriategastroin-
testinal investigation and making a conﬁdent diagnosis of
NCCP. Once this has been established, a trial of a PPI should
be the next step. Subsequent investigation should be kept
to a minimum and a variety of other medications can be
tried although the tricyclic antidepressants are probably the
mosteﬀective.Ifpharmacologicalapproachesfail,behavioral
treatments can be of value depending on their availability.
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